NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.67 +0.65 (+0.83%) GOLD FUTURES
2,393.80 +33.90 (+1.44%) DOW
39,836.13 +278.02 (+0.70%) Bitcoin GBP
51,605.07 +3,245.21 (+6.71%)
Alto Neuroscience, Inc. (ANRO)
| Previous close | 14.16 |
| Open | 14.00 |
| Bid | 13.86 x 1100 |
| Ask | 13.99 x 800 |
| Day's range | 13.83 - 14.67 |
| 52-week range | 12.78 - 24.00 |
| Volume | |
| Avg. volume | 177,118 |
| Market cap | 372.612M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
LOS ALTOS, Calif., May 14, 2024--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.
- Business Wire
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
LOS ALTOS, Calif., May 09, 2024--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) today announced upcoming data presentations that highlight the company’s precision psychiatry pipeline and biomarker-based analyses at the Society of Biological Psychiatry (SOBP) and American Society of Clinical Psychopharmacology (ASCP) Annual Meetings, to take place May 9-11 in Austin, TX, and May 28-31 in Miami Beach, FL, respectively.
- Business Wire
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
LOS ALTOS, Calif., April 23, 2024--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) today announced positive results from its healthy volunteer Phase 1 study of ALTO-101, a novel PDE4 inhibitor in development for cognitive impairment associated with schizophrenia (CIAS). Results from the study demonstrated favorable tolerability and improved pharmacokinetics of ALTO-101 when administered via a transdermal delivery system (TDS) compared to oral administration. The TDS formulation is being developed
